ERBB2 and breast carcinoma: Our previous studies have shown that continued use of trastuzumab in PTEN-deficient breast cancer cells induced the EMT in bulk cell lines, increased BCSC characteristics, and transformed HER2+ to a triple negative phenotype [10, 14].